Especially in HGF/C-Met metastatic tumors, such as breast and prostate cancer cells, pharmacological inhibition alone does not reduce the phosphorylation of liver growth factor (HGF) receptor c-Met and NF-κB activity and reduce the migration of cancer cells without MCT1 knockdown. This evidence concerns the gene SLC16A1 and cancer.